%0 Journal Article
%T NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024.
%A Gotlib J
%A Gerds AT
%A Abdelmessieh P
%A Ali H
%A Castells M
%A Dunbar A
%A Fein Revell R
%A George TI
%A Green S
%A Gundabolu K
%A Hexner E
%A Jain T
%A Jamieson C
%A Kaesberg PR
%A Kuykendall AT
%A Madanat Y
%A Manchanda N
%A Masarova L
%A May J
%A McMahon B
%A Mohan SR
%A Nadiminti KV
%A Oh S
%A Palmer J
%A Patel A
%A Patel AA
%A Podoltsev N
%A Rein L
%A Salit R
%A Talpaz M
%A Wadleigh M
%A Wall S
%A Bergman MA
%A Hochstetler C
%J J Natl Compr Canc Netw
%V 22
%N 2
%D 2024 Jun
%M 38862005
%F 12.693
%R 10.6004/jnccn.2024.0030
%X Mastocytosis is a heterogeneous group of disorders comprising cutaneous mastocytosis, systemic mastocytosis, and mast cell sarcoma. It is associated with a variety of symptoms related to the release of mast cell mediators and mast cell tissue infiltration. Referral to specialized centers with expertise in the management of mastocytosis and multidisciplinary collaboration with subspecialists (eg, allergists for the management of anaphylaxis and drug hypersensitivities, anesthesiologists for invasive procedures or surgery, high-risk obstetrician for pregnancy) is recommended. The NCCN Guidelines for Systemic Mastocytosis provide evidence- and consensus-based recommendations for the diagnosis and comprehensive care of patients with systemic mastocytosis. The multidisciplinary panel of experts convenes at least once a year to review requested changes to the guidelines from both internal and external entities as well as to discuss data on existing and new therapies. These NCCN Guidelines Insights focus on some of the recent updates to the guidelines.